- Immunization:
- Adults & children over 6 months: SC 0.5mL 10 days before travel
Injection: 17D strain
- For high risk patients include travel or residence in yellow fever endemic area and yellow fever lab workers
- Repeat dose x1 prior to next travel with exposure risk if pregnant at time of 1st dose or if stem cell transplant after last dose
- Repeat dose every 10 years if HIV-positive with exposure risk, lab worker with low antibody titer or higher risk travel
Live, attenuated virus stimulates active immunity to Yellow Fever
It is thought to convey active immunity via stimulation of production of endogenously produced antibodies
- Injection site reaction
- Headache
- Fever
- Myalgia
- Malaise
- Asthenia
- Rash
- Patients <6 months
- Hypersensitivity to class/compounds
- Hypersensitivity to gelatin
- Hypersensitivity to egg or egg product
- Hypersensitivity to chicken protein
- Breastfeeding if infant <9 months
- Immunocompromised patients
- Symptomatic HIV infection
- HIV infection with CD4 <200
- HIV infection with CD4 <15% (patients <6 years old)
- Thymic disease history
- Belimumab
- Certolizumab pegol
- Ibrutinib
- Ifosfamide
- Methotrexate
- Oxaliplatin
- Procarbazine
- Secukinumab
Drug Status
| Availability | Prescription only |
| Pregnancy | Category C |
| Breastfeeding | Avoid use while breastfeeding infants <9 months unless travel to endemic area cannot be avoided or postponed |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Stamaril | FDC | Injection | 1D, 10D | Sanofi Pasteur | Ressourcethica Kenya |